Fagron Sa Ord

Good day and welcome to the conference call regarding the Q1 results of Fagron. Today's conference is being recorded. At this time, I would like to turn the conference over to Fagron. Please go ahead.

Thank you, operator. Good morning to you all and thank you for joining the first quarter of 2021 Trading Update Conference Call of Fagron. We will start the call with a presentation on the highlights of the first quarter by our CEO, Rafael Padilla, and our CFO, Karen de Jong. The presentation can be downloaded at our website, investors.vagon.com. After the introduction of Rafael, we will open the line for Q&A. Rafael will conclude the call with some closing remarks. Rafael, Karen, please go ahead. Thank you very much, Constantine.

Good morning, all of you. We start the presentation at slide number three with a consolidated turnover of this first quarter of 2021, where we see a decrease of 4.8%, though an increase in constant exchange rate, total growth of almost 5%, and organically 2.6% at constant exchange rates. When we look at the regions, EMEA at almost 47%, Latin America almost 24%, and Northern America at 29.5%. Looking at the segments, essentials, of course, 50% of our revenues, FCS, compounding services, both sterile and non-sterile at 28.3%, our premium pharmaceuticals, niche pharmaceuticals, almost at 2%, and we are very happy to announce the 19.6% of brands that has increased also when we compare to last year. On the right side, we see a photo of one of our colleagues in one of our 11 Clearrooms in Wichita, Kansas, FSS US, working with one of the four robots that we have now for the IV bags. We move to the next slide.